AU2003225670A1 - Interferon drug therapy for the treatment of viral diseases and liver fibrosis - Google Patents

Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Info

Publication number
AU2003225670A1
AU2003225670A1 AU2003225670A AU2003225670A AU2003225670A1 AU 2003225670 A1 AU2003225670 A1 AU 2003225670A1 AU 2003225670 A AU2003225670 A AU 2003225670A AU 2003225670 A AU2003225670 A AU 2003225670A AU 2003225670 A1 AU2003225670 A1 AU 2003225670A1
Authority
AU
Australia
Prior art keywords
treatment
drug therapy
liver fibrosis
viral diseases
interferon drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003225670A
Inventor
Lawrence M. Blatt
Henry H. Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AU2003225670A1 publication Critical patent/AU2003225670A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2003225670A 2003-02-28 2003-02-28 Interferon drug therapy for the treatment of viral diseases and liver fibrosis Abandoned AU2003225670A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/006687 WO2004078194A1 (en) 2003-02-28 2003-02-28 Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Publications (1)

Publication Number Publication Date
AU2003225670A1 true AU2003225670A1 (en) 2004-09-28

Family

ID=32961111

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003225670A Abandoned AU2003225670A1 (en) 2003-02-28 2003-02-28 Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003287145A Abandoned AU2003287145A1 (en) 2003-02-28 2003-10-14 Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003287145A Abandoned AU2003287145A1 (en) 2003-02-28 2003-10-14 Interferon drug therapy for the treatment of viral diseases and liver fibrosis

Country Status (5)

Country Link
JP (1) JP2006522008A (en)
CN (1) CN1764475A (en)
AU (2) AU2003225670A1 (en)
CA (1) CA2516776A1 (en)
WO (2) WO2004078194A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034764B2 (en) * 2003-10-21 2011-10-11 Medtronic Minimed, Inc. Modulation of SOCS expression in therapeutic regimens
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
EP2032134B1 (en) * 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
KR20150085139A (en) 2007-10-05 2015-07-22 젠자임 코포레이션 Method of treating polycystic kidney diseases with ceramide derivatives
EP2320886B1 (en) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010039256A1 (en) 2008-10-03 2010-04-08 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107925A (en) 2011-10-21 2014-12-03 Abbvie Inc TREATMENT OF AAD COMBINATION (EG WITH ABT-072 OR ABT-333) FOR USE IN HCV TREATMENT
ES2529143B1 (en) 2011-10-21 2015-10-26 Abbvie Inc. COMBINATION OF AT LEAST TWO DIRECT ACTION ANTIVIRAL AGENTS, RIBAVIRINE BUT NOT INTERFERONED FOR THE USE OF HCV TREATMENT
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne.
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon

Also Published As

Publication number Publication date
JP2006522008A (en) 2006-09-28
WO2004078194A1 (en) 2004-09-16
AU2003287145A1 (en) 2004-09-28
CA2516776A1 (en) 2004-09-16
WO2004078193A1 (en) 2004-09-16
CN1764475A (en) 2006-04-26

Similar Documents

Publication Publication Date Title
IL165860A0 (en) Administration of therapeutic viruses
AU2003220317A1 (en) Methods and drug delivery systems for the treatment of orofacial diseases
IL157364A0 (en) Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
AU2002329990A1 (en) Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
AU2003261251A1 (en) Methods of delivering therapeutic agents
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
AU2002322719A1 (en) Delivery of therapeutic capable agents
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003259381A1 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
EP1572709A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
AU2003287145A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1095036A1 (en) Virus therapeutic drug
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003273983A1 (en) Viral vectors and the use of the same for gene therapy
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
AU2003256280A1 (en) Methods of delivering gene therapy agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase